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Microwave imaging for neoadjuvant
chemotherapy monitoring: initial clinical
experience
Paul M Meaney1*, Peter A Kaufman2, Lori S Muffly2, Michael Click3, Stephen P Poplack3, Wendy A Wells4,
Gary N Schwartz2, Roberta M di Florio-Alexander3, Tor D Tosteson5, Zhongze Li5, Shireen D Geimer6,
Margaret W Fanning7, Tian Zhou8, Neil R Epstein1 and Keith D Paulsen1
Abstract
Introduction: Microwave tomography recovers images of tissue dielectric properties, which appear to be specific
for breast cancer, with low-cost technology that does not present an exposure risk, suggesting the modality may
be a good candidate for monitoring neoadjuvant chemotherapy.
Methods: Eight patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer were imaged
longitudinally five to eight times during the course of treatment. At the start of therapy, regions of interest (ROIs)
were identified from contrast-enhanced magnetic resonance imaging studies. During subsequent microwave
examinations, subjects were positioned with their breasts pendant in a coupling fluid and surrounded by an
immersed antenna array. Microwave property values were extracted from the ROIs through an automated
procedure and statistical analyses were performed to assess short term (30 days) and longer term (four to six
months) dielectric property changes.
Results: Two patient cases (one complete and one partial response) are presented in detail and demonstrate
changes in microwave properties commensurate with the degree of treatment response observed pathologically.
Normalized mean conductivity in ROIs from patients with complete pathological responses was significantly
different from that of partial responders (P value = 0.004). In addition, the normalized conductivity measure also
correlated well with complete pathological response at 30 days (P value = 0.002).
Conclusions: These preliminary findings suggest that both early and late conductivity property changes correlate
well with overall treatment response to neoadjuvant therapy in locally advanced breast cancer. This result is
consistent with earlier clinical outcomes that lesion conductivity is specific to differentiating breast cancer from
benign lesions and normal tissue.
Introduction
Neoadjuvant chemotherapy (NCT) for breast cancer has
become an increasingly important treatment option [1]
that offers potential therapeutic advantages. Various clini-
cal trials have demonstrated that treatment response,
including tumor shrinkage, leads to substantial downsta-
ging of disease which in turn allows for increased use of
more limited surgery [1]. In such cases, breast conservation
strategies such as lumpectomies and radiotherapy can be
used instead of more comprehensive radical mastectomies
[2]. By monitoring the patient’s response to systemic
therapy before tumor resection, prediction of longer term
prognosis or identification of the need for additional or
alternative treatment may be possible. Data have suggested
that patients receiving neoadjuvant therapy with pathologic
complete response have better survival outcomes [1,3].
While NCT is emerging as a promising treatment strat-
egy for locally advanced breast cancer, deploying moni-
toring methods during the course of therapy is important
for making further advances. Magnetic resonance (MR)
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and fluorodeoxyglucose positron emission tomography
(FDG PET) have been evaluated in several clinical trials
and have proven useful in this setting, but both also
come at considerable cost and inconvenience [3-8].
Conventional breast imaging modalities, such as ultra-
sound and mammography, have been disappointing in
detecting the extent of residual disease during treatment
[9]. Studies have also been conducted using Doppler
ultrasonography, diffuse optical spectroscopy and tomo-
graphy and scintimammography [10-13]. Assessing
tumor shrinkage by clinical breast examination is possi-
ble as well but is poorly correlated with treatment
response [1].
Microwave imaging is in the early stages of clinical eva-
luation and most of the work has focused on breast tumor
detection. Impressive technical developments based on
active microwave radar concepts have been reported
[14-18]. Passive microwave radiometry has also been
investigated [19-21]. However, only a modest number of
clinical microwave tomographic (MT) breast examinations
have been conducted [22-24]. Our early clinical experience
with MT has demonstrated statistically significant differ-
ences in the electrical conductivity of breast tumors
greater than 1 cm in diameter relative to the normal breast
and other benign abnormalities [25]. We have also shown
strong associations between whole breast radiographic
density designations as well as focal patterns of dense
fibroglandular tissue and the imaged microwave property
distributions [26].
We are currently evaluating women undergoing NCT
for the treatment of locally-advanced breast cancer with
MT performed at regular intervals from the start of treat-
ment to the time of surgery. In the following sections, we
describe the methods used in the study related to patient
recruiting, imaging modalities, pathology and image analy-
sis. In the Results section, we examine two cases in detail
(one complete responder and a second non-responder) to
provide an appreciation of the information contained in
the images and their progression during treatment. In
addition, we also include a representative sequence of
images from the contralateral breast for one patient during
the course of treatment as an example of the more limited
changes observed in the non-cancerous breast. Finally, we




The microwave imaging study was Health Insurance Port-
ability and Accountability Act (HIPAA) compliant and
approved by the institutional review board (IRB) at Dart-
mouth. These experiments comply with the current laws
of the United States of America. All patients provided
written informed consent and were compensated for their
participation. Eight women enrolled in a pilot study,
successfully completed their treatment and corresponding
series of MT examinations. These patients proceed
through the prescribed chemotherapy regimen until sur-
gery as part of standard-of-care breast cancer manage-
ment. In most cases, MR images of both breasts were
acquired just prior to therapy and again after treatment
but before surgery (one case was followed with ultrasound
examinations). After surgery, all breast tissue was analyzed
in Surgical Pathology at Dartmouth-Hitchcock Medical
Center (DHMC) to document the extent of treatment
response. Table 1 summarizes the patient information for
the subjects enrolled in this pilot stage of our study.
Microwave Tomography
For each TM session, patients lie prone on a padded
table with one breast pendant through an aperture into
a coupling liquid. An array of monopole antennas with
fixed radial positions on a 15.2 cm diameter circle are
moved up from the base of the imaging tank into a
position surrounding the breast close to the chestwall.
Data are acquired over multiple frequencies (700 to
1,700 MHz in 200 MHz increments) with each antenna
sequentially acting as the transmitter and the remaining
complement serving as receivers for a total of 240 (16
transmitters × 15 receivers) measurements at each fre-
quency. The antennas are subsequently moved to six
lower positions in 1 cm increments (or less depending
on the overall breast length) where the data acquisition
sequence is repeated to provide coverage of the breast.
After data acquisition is completed on one breast, the
patient is repositioned and the contralateral breast is
imaged under the same protocol for a total examination
time of approximately 15 minutes (approximately 5 min-
utes of data acquisition time per breast and 5 minutes
for breast positioning).
We utilized either 80% or 86% glycerin coupling baths
for patient examinations. At the first pre-therapy imaging
session, baseline data were acquired with both baths for
each patient. We determined the optimal bath for a given
subject by evaluating the measured data and image quality
from both acquisitions [26]. Given the variability of the
average microwave properties of the breast, especially with
respect to its density and the patient’s age, we compared
the recovered images empirically on a patient-by-patient
basis in order to determine the best mixture for future
examinations [24]. Once the bath of choice was estab-
lished, the liquid was recycled and used only for the subse-
quent examinations of that individual patient.
Permittivity and conductivity images were recon-
structed post-examination for associated frequencies and
antenna positions. Each image was processed in less than
two minutes on a Dell Blade workstation using our two-
dimensional finite difference time domain (FDTD)-based
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algorithm which has been described in detail elsewhere
[27-30].
Image analysis
Regions of interest (ROIs) were determined for each set of
permittivity and conductivity images at 1,300 MHz which
proved to be the most reliable and highest resolution
images obtained over all patients and examination dates.
Each ROI was selected at one array position based on
knowledge of the central tumor location from information
provided by the attending oncologist with support from
the study radiologists - both in terms of distance from the
chestwall and spatially within the anatomically coronal
plane. Given that breast positioning from examination to
examination was not identical, and that the breast may
change size over the course of therapy due to structural
and compositional changes from treatment, care was exer-
cised to align the ROI plane between sessions. Similarly-
sized regions were also applied to reduce the comparison
bias between examinations. The same process was per-
formed to define representative non-tumor tissue ROIs for
generating the background metrics used in the analysis. A
graphical user interface was used to identify each zone and
compute the microwave property averages and associated
standard deviations automatically. Figure 1 shows a repre-
sentative example of a set of breast images used in the
analysis. The ROIs resulted from planes where the tumors
were dominant in the permittivity and conductivity
images. The background zones were selected from planes
farther away from the dominant tumor cross-sections to
minimize any influences of the elevated tumor properties
on the background estimate that can occur from the
smoothing characteristics of the image regularization
process. In addition, because the normal sections of the
breast contain zones of adipose and fibroglandular tissue,
and the properties of the latter are known to vary consid-
erably, we chose background regions consisting primarily
of adipose tissue (as demonstrated by their very low prop-
erty values) as a stable and consistent baseline for the
duration of the study [31].
Clinical (MR) imaging
MR breast images were acquired in a 1.5T scanner (GE
Signa, GE Healthcare, Waukesha, WI, USA) for standard
clinical indications or a 3T (Philips Achieva, Philips
Healthcare, Andover, MA, USA) system for research stu-
dies. Dedicated breast coils were used with sub-millimeter
in-plane resolution and slice thicknesses of < 3 mm (T1-
weighted) and < 5 mm (T2-weighted). T1 and T2 scans
provided detailed maps of tissue structure which were
used to differentiate breast tissue types. Three dimensional
gradient echo T1-weighted sequences with chemical fat
suppression were performed prior to and at one to two
minute intervals following the injection of a bolus of con-
trast (Gadodiamide, Omniscan, GE Healthcare) of 0.1
mmol per kilogram of body weight to identify suspicious
enhancement foci. The first post-contrast scan was
initiated 40 seconds after injection. Subtraction images
were generated with the pre-contrast gradient echo T1
image as the reference to assess the Gd washout behavior.
Pathology
Standard surgical pathology analysis of the excised tissues
was used to assess subject outcomes. The subjects com-
pared in this pilot study underwent surgical mastectomy
[32]. The mastectomy specimens were sectioned fresh,







Pathology Exams Treatment Radiographic Response Pathologic
Response
1 SC 7 × 6.5 IDC, ER+/PR-/HER2neu+ 7 AC2/paclitaxel
trastuzumab
Yes (MRI) pCR
2 HD 5 × 3 IDC, ER-/PR-/HER2neu- 7 paclitaxel tocosol No substantial response
(MRI)
pPR2
3 SC 4 × 4 IDC, ER-/PR-/HER2neu- 5 TAC3 Yes (MRI) pCR
4 HD 5 × 5 IDC, ER+/PR+/HER2neu+ 5 AC2/paclitaxel
trastuzumab
Yes (MRI) pCR
5 ED 8 × 7 IDC, ER+/PR+/HER2neu- 10 AC2/paclitaxel No substantial response
(MRI)
pPR4
6 HD 1 × 1 IDC, ER equivocal/PR-/
HER2neu+
8 Taxol/FEC/Herceptin Yes (MRI) pCR
7 ED 10 × 9 IDC, ER-/PR-/HER2neu+ 4 TAC3 Yes (MRI) pPR1
8 HD 4 × 4 IDC, ER+/PR+/HER2neu+ 5 TAC3 No substantial response
(MRI)
pPR3
AC2, doxorubicin and cyclophosphamide; ED, extremely dense; ER, estrogen receptor; HD, heterogeneously dense; HER2-neu, human epidermal growth factor
receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; pPR1, near total treatment effect (< 10% of tumor remaining) [32]; pPR2, evidence of
response to therapy but with 10% to 50% of tumor remaining [32]; pPR3, evidence of response to therapy but with > 50% < 90% of tumor remaining [32]; pPR4,
minimal evidence of response to therapy with > 90% of tumor remaining [32]; PR, progesterone receptor; SC, scattered; TAC3, docetaxel, doxorubicin, and
cyclophosphamide.
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medial to lateral, in the sagittal plane. Each tissue slice
was examined grossly and photographed for image corre-
lation. Areas of treatment response, residual tumor and
normal breast were sampled and processed for micro-
scopic analysis per standard laboratory protocols (forma-
lin fixation, dehydration, paraffin-embedding, 4 micron
sectioning and H & E stain). Complete pathologic
response (pCR) was defined as a complete absence patho-
logically of cancer in the breast after extensive sampling.
Results and discussion
Case I - complete response
The first patient had a locally advanced cancer on the right
side. At diagnosis, the right breast mammogram showed
linear and pleomorphic micro-calcifications in a segmental
distribution over the lower-central and entire lower-inner
gradient while also demonstrating skin thickening in over-
lying zones. The tumor measured 6.5 × 3.7 × 7.1 cm by
MRI. Biopsy demonstrated an intermediate grade invasive
ductal carcinoma with a component of ductal carcinoma
in situ (DCIS), estrogen receptor positive (ER(+)), proges-
terone receptor negative (PR(-)), human epidermal growth
factor receptor-2 (HER-2)/neu(+) (HER-2:CEP-17 14.2).
The patient was treated with four cycles of doxorubicin
and cyclophosphamide, followed by four cycles of weekly
paclitaxel and traztuzumab (PT) and then underwent
modified radical right mastectomy. Surgical pathology
revealed a complete pathologic response.
Contrast-enhanced MRI was performed prior to treat-
ment, at day 85, and at completion of neoadjuvant ther-
apy prior to surgery. Figure 2a shows a sequence of
corresponding sagittal images of the right breast prior to
treatment consisting of (i) a baseline T2 sequence, (ii) a
gadolinium enhancement image and (iii) a baseline sub-
traction image. The dominant feature reveals a large dis-
persed tumor in the lower portion of the breast extending
Figure 1 1300 MHz permittivity (top row) and conductivity (bottom row) images for all 7 planes. Breast perimeter, and tumor ROI and
background zones used in the analysis are indicated. ROI, region of interest.
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from the nipple to the chestwall. Enhancement of lymph
nodes in the upper right corner of the images is also evi-
dent. The contrast enhanced image exhibits significant
skin thickening around most of the breast, but especially
near the nipple. In addition, the T2 image shows substan-
tial edema (because it does not enhance in the subtraction
image) under the skin in the regions near the nipple
which is due to the dermal lymphatics. The correspond-
ing images at day 85 (Figure 2b) show enhancement in
the same span from the nipple to the chestwall but at a
reduced level, indicative of response at this intermediate
point during treatment. By this time, the skin has also
thinned considerably with a corresponding reduction in
edema.
MT was conducted prior to the start of therapy, five
other times during treatment and just prior to surgery.
Figure 3 shows the recovered, en face permittivity and
conductivity images for anatomically coronal planes 5, 6
and 7 (Plane 1 is closest to the chestwall and subsequent
planes move away in 1 cm increments) for (a) the left
(contralateral) breast before chemotherapy, (b) the right
(ipsilateral) breast before chemotherapy, (c) the right
breast at day 44, and (d) the right breast after therapy.
For the left breast, the tissue boundary is readily evident
and decreases in size from plane 5 to 7 as expected.
Both permittivity (εr) and conductivity (s) images show
the breast exhibiting relative low values with a some-
what elevated central region most likely associated with
higher water-content fibroglandular tissue [31].
For the right (diseased) breast images prior to treat-
ment, the coronal perimeters are more uneven with ele-
vated property zones in the lower quadrants and
increased properties on the breast boundary likely corre-
sponding to the tumor, skin thickening and edema
appearing in the MRI, respectively. At day 44 (Figure 3c)
the baseline MT images have changed significantly and
show: (1) improved delineation of the breast boundary,
(2) diminished tumor size and property intensity, and
Figure 2 Sagittal MR images of the right breast of a patient with a complete pathologic response: (a) images prior to therapy and (b)
at day 85. For each set, (i) is a T2-weighted image, (ii) is a contrast-enhanced image from a SPGR sequence, and (iii) is a subtraction image
between (ii) and a pre-contrast baseline, respectively. MR, magnetic resonance; SPGR, spoiled gradient recalled.
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(3) reduced property intensity along the lower breast
edge. All three findings appear to correspond well with
the clinical tumor size reduction, skin thinning and
decrease in subdermal edema. At the end of treatment,
the breast outline is even more regular than in the pre-
vious images, the recovered tumor enhancement is
Figure 3 1300 MHz microwave tomographic images. Imaging planes five to seven are shown corresponding to the three closest planes to
the nipple with the permittivity on the top row and conductivity on the bottom row. (a) Left (contralateral) breast prior to treatment, (b) right
(ipsilateral) breast prior to treatment, (c) right breast 44 days into treatment, and (d) right breast immediately prior to surgery.
Meaney et al. Breast Cancer Research 2013, 15:R35
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further reduced and no enhancement appears near the
breast perimeter.
A significant reduction in the recovered dielectric
properties occurred within the tumor region as treat-
ment progressed. The post-surgical pathological evalua-
tion confirmed a complete response. Larger areas of
soft, grey-white tissue appear where the tumor had been
treated. Microscopic analysis showed no signs of viable
tumor with only stromal scarring, macrophages and
inflammation in the treated areas. Dielectric probe mea-
surements in pathology revealed that the treated tumor
properties have not reverted back to values correspond-
ing to fibroglandular zones in the contralateral breast as
expected since the treated area is no longer representa-
tive of normal breast tissue.
Figure 4 summarizes the 1,300 MHz ROI:background
property ratios as a function of time for all MT exami-
nations during treatment of this patient. The permittiv-
ity ratio decreased somewhat unevenly and had a total
reduction of 38% from the start to end of treatment.
The εr value did not drop below 89% of its initial level
until the day 114 examination. The conductivity ratio
exhibited a more dramatic and earlier reduction - 56%
decrease after 23 days and 82% decrease after treatment
completion, respectively, which is consistent with our
previous clinical results that indicated the conductivity
images are significantly more sensitive to the presence
of tumor than their permittivity partners.
Case II - non-responder
The second case was a woman who presented with locally
advanced and metastatic breast cancer. Initial MRI showed
a 4 × 2.5 × 4 cm irregular complex cystic mass in the
upper outer quadrant of the left breast. Two smaller (1 cm)
lesions were noted superior and anterior to the primary
tumor. Core needle biopsy of the primary tumor
demonstrated a high grade invasive ductal carcinoma with
angiolymphatic invasion, weakly ER(+), PR(-), HER-2/neu
(-) (HER-2:CEP-17 1.09). Left axillary lymph node biopsy
was positive for metastatic disease. The patient was treated
with four cycles of single agent weekly TOCOSOL pacli-
taxel (Eagle Pharmaceuticals, Belgrade, Serbia), followed by
left simple mastectomy. Surgical pathology revealed a par-
tial pathologic response with the treatment effect estimated
as comprising > 50% but < 90% of the original tumor.
MR images were obtained throughout neoadjuvant
treatment and two weeks prior to mastectomy (day 85).
Figure 5a shows a sequence of corresponding sagittal
images of the left breast prior to treatment with (i) a T2
sequence, (ii) a gadolinium enhancement image and (iii)
a baseline subtraction image. The pre-treatment MR
images presented a large mass with in-plane gadoli-
nium-enhancing dimensions of 4.7 × 2.6 cm and a sec-
ondary satellite (anterior) enhancement. A large water
filled cavity (seroma resulting from an earlier biopsy)
appeared directly adjacent to the tumor. Figure 5b
shows the corresponding images for day 52 which exhi-
bit a more pronounced tumor adjacent to the seroma
(visible as a dark region in the subtraction image) with
distinct spiculations radiating from the center. This MR
set showed an enhancing zone of 3.5 × 4.3 cm in a similar
area with possible progression anteriorly. The washout
kinetics were similar to those of the first examination.
A later study at day 85 indicates that the satellite lesion
became more active in terms of its enhancement/rapid
washout rate suggesting tumor progression in this area. By
the time of the last MR (not shown), the gadolinium-
enhancing zone had grown to 5.4 × 3.9 cm and showed
washout kinetics indicative of malignant progression. This
study suggested that the larger primary mass had merged
with the secondary satellite focus evident in the first
examination.
Figure 4 Summary of the permittivity and conductivity region of interest (ROI) analysis for the MT imaging sessions from the start of
treatment until just prior to surgery. MT, microwave tomography.
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MT was conducted prior to the start of therapy, at
five times during treatment and just prior to surgery.
Figure 6 shows the reconstructed images for planes two
to six (1.0 cm increments) for (a) the right breast at the
start of chemotherapy and for the left breast at (b) the
start of chemotherapy, (c) day 28, and (d) just prior to
Figure 5 Sagittal MR images of the left breast of a patient with pathologic non-response: (a) images prior to therapy, (b) images on
day 52, and (c) images prior to surgery. For each set, (i) is a T2-weighted image, (ii) is a contrast-enhanced image using an SPGR sequence,
and (iii) is a subtraction image between (ii) and a baseline, respectively. MR, magnetic resonance; SPGR, spoiled gradient recalled.
Meaney et al. Breast Cancer Research 2013, 15:R35
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surgery. The right breast images present relatively
homogeneous dielectric properties in all planes, except
for an elevated zone in the lower central to lower-right
quadrant which probably corresponds to a concentration
of fibroglandular tissue. As is typical with these images,
the outline of the breast is evident and decreases in
Figure 6 1300 MHz microwave tomographic images. Imaging planes two to six are shown corresponding to the five closest planes to the
nipple with the permittivity on the top row and conductivity on the bottom row. (a) Right (contralateral) breast prior to treatment, (b) left
(ipsilateral) breast prior to treatment, (c) left breast 57 days into treatment, and (d) left breast immediately prior to surgery.
Meaney et al. Breast Cancer Research 2013, 15:R35
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diameter as the planes progress towards the nipple.
Some artifacts appear in plane two (closer to the chest-
wall), especially an unevenness in the breast permittivity
perimeter and a slightly elevated zone in the upper-left
edge of the conductivity image. These artifacts are fairly
common occurrences in our images, especially for larger
breasts and those with very high property contrast with
the coupling bath, and have been noted previously in
Meaney et al. [26,33].
For the left breast images, the outer boundaries appear
more disrupted than in the contralateral breast and signifi-
cant internal zones of both permittivity and conductivity
enhancement are evident. Enhancement occurs in the
upper-central to upper-right regions in planes two to four
of the permittivity and planes two to five of the conductiv-
ity images at the first two imaging dates (pre-chemotherapy
and day 52). This visibility over multiple planes is indicative
of a large tumor. The enhanced area in plane four of the
permittivity image from the second examination is much
more intense (higher values) than the corresponding plane
for the first examination and appears to corroborate the
MR observation that the tumor was growing. The micro-
wave images obtained from the last examination suggest
that the tumor has expanded significantly in size with the
appearance of substantial enhancement in both planes five
and six. The level of enhancement in the conductivity
images has also increased correspondingly. These results
correlate well with the clinical observations that the tumor
spread anteriorly towards a satellite location and that the
primary and secondary tumors had merged by the time of
surgery.
Figure 7 summarizes the ROI:background ratios for both
the permittivity and conductivity images as a function of
time. In this case, the permittivity ROI:background values
remain relatively constant but then increase dramatically
towards the end of treatment. The corresponding conduc-
tivity ratios are much more uneven with sharp increases at
day 2 and day 28. The uneven behavior may be due in
part to the fact that the tumor did appear to partially
respond in some areas (for example, during the first 21
days) but then expanded towards the anterior portion of
the breast. Nonetheless, the ROI:background values did
not decrease appreciably at any extended duration during
treatment and are consistent with the pathological deter-
mination of non-response.
Contralateral example
For comparison, we also collected data from the contralat-
eral breast when possible (that is, examination time-
permitting, patient not feeling ill, and so on) and show
example images from planes one to four for Patient #8 at
the first date, day 33 and day 62 after the start of treat-
ment (Figure 8). In these images, the permittivity and con-
ductivity outlines of the breast are evident in terms of a
property gradient with the background coupling fluid. As
the images progress from plane one to four, the overall
breast diameter decreases - a feature that is more obvious
in the conductivity results. In the permittivity images, an
annulus of lower property tissue surrounds a more ele-
vated zone in each of the four planes. This central region
contains more fibroglandular tissue for which higher per-
mittivity properties are expected relative to the surround-
ing adipose tissue. In the conductivity images, the first two
planes also show elevated property zones towards the
lower right quadrant; however, they begin to disappear in
planes three and four as the overall size of the breast
cross-section shrinks, and the increased fibroglandular
tissue properties begin to blur with the higher properties
of the surrounding coupling liquid. The images for all
three examination dates are similar and do not suggest
Figure 7 Summary of the permittivity and conductivity region of interest (ROI) analysis for the MT imaging sessions from the start of
treatment until just prior to surgery. MT, microwave tomography.
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significant changes other than from minor shifting of the
position of the breast within the field of view.
We were not always able to collect as much data from
the contralateral breast as for the ipsilateral (diseased)
side for multiple reasons: (a) several patients had ports
inserted in the contralateral breast for drug infusion
that precluded imaging, (b) multiple experimental ima-
ging modalities were involved in the study, so the total
Figure 8 1300 MHz microwave tomographic images of the contralateral breast for Patient 8. Imaging planes one to four are shown
corresponding to the four closest planes to the chest wall with the permittivity on the top and conductivity on the bottom row, respectively.
(a) Prior to treatment, (b) day 33, and (c) day 62.
Meaney et al. Breast Cancer Research 2013, 15:R35
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examination time allotted to MT was limited, and (c)
some patients were simply feeling too ill to participate
in more than a single-sided breast examination.
Summary of the eight patient study
We studied the normalized ROI:background outcome
ratios with respect to baseline as a function of time after
initiation of treatment for all eight subjects (four com-
plete response, four incomplete (non)-response). Figure 9
shows a summary of the data points for all eight patients.
We applied a linear mixed model with random intercept
(subject) and slope effects to analyze both permittivity
and conductivity separately. We used the restricted maxi-
mum likelihood (REML) method to estimate coefficients.
Figure 9 Summary of the permittivity and conductivity region of interest (ROI) analysis for the MT imaging sessions for all patients
during treatment. MT, microwave tomography.
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Covariates included in the model were group (1 = com-
plete responder and 0 = non-responder), days from base-
line, and interactions between group and days from
baseline. Days from baseline was treated as a continuous
variable. SAS 9.2 (SAS Institute Inc., Cary, NC, USA) was
used to conduct all statistical analyses. Two-side signifi-
cance level was set at 5%. In order to ensure that the
estimated upper and lower value bounds be positive, all
statistical analyses were based on the natural log trans-
formed normalized outcome and then transformed back
for figure presentation. Figures 10a and 10b show the
permittivity and conductivity plots from the fitted analy-
sis curves for the complete-responder and incomplete
(non)-responder groups.
Figure 10 Fractional change summary for all patients for the 1300 MHz permittivity and conductivity ROI:Background ratios over the
full course of treatments. Dashed lines indicate the 95% confidence intervals for the Responder (in blue) and Non-responder (in red) curves
for permittivity in (a) and conductivity in (b). ROI, region of interest.
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The mean of the normalized permittivity ROI:back-
ground ratio for complete responders was not signifi-
cantly different from that for incomplete-responders (P-
value = 0.68) over the full treatment intervals. However,
the corresponding normalized mean conductivity for the
complete responders was significantly different from
that for non-responders (P-value = 0.004). There were
no significant time or interaction effects for either
dielectric property in the study. We investigated whether
other covariates, including body mass index (BMI), age
and breast density (we grouped fatty and scattered den-
sity breasts into a single low density category, and het-
erogeneously dense and extremely dense breasts into
one high density group, respectively) influenced the
Figure 11 Fractional change summary for all patients for the 1300 MHz permittivity and conductivity ROI:Background ratios over the
full course of treatment with outliers removed. Dashed lines indicate the 95% confidence intervals for the Responder (in blue) and Non-
responder (in red) curves for permittivity in (a) and conductivity in (b). ROI, region of interest.
Meaney et al. Breast Cancer Research 2013, 15:R35
http://breast-cancer-research.com/content/15/2/R35
Page 14 of 16
results. For both permittivity and conductivity, the effect
of these factors was not significant (P-values for the
three variables were 0.84, 0.36 and 0.32 for permittivity,
respectively, and 0.41, 0.58 and 0.07 for conductivity,
respectively). We also analyzed the interaction between
the group and days from baseline variables and found
no association (P-values of 0.14 and 0.28 for the permit-
tivity and conductivity, respectively). These results are
consistent with our prior experience in which conduc-
tivity was found to have a higher level of correlation
with tumor presence than the corresponding permittiv-
ity values and would be expected to be the superior
measure of tumor progression/regression [25]. In addi-
tion, the normalized conductivity measure had a high
level of association with complete tumor response at 30
days (P-value = 0.002) - a finding that could be clinically
important because it would provide valuable early-stage
information on tumor progression and whether the cur-
rent therapy regimen should be continued or modified.
Finally, we assessed whether outliers may have influ-
enced these results. After removing the data point from
Patient #2 on day 104 for both permittivity and conduc-
tivity, we compared outcomes between the two groups
with the same statistical model described above. In this
instance, significant differences resulted between the
responder and non-responder groups for both permittiv-
ity and conductivity; the P-values were 0.0024 and
0.0019, respectively (Figures 11a and 11b). This outcome
confirms our hypothesis that the conductivity is statisti-
cally significant; however, the permittivity becomes sta-
tistically significant when the data point is removed.
While likely caused by the fact that the study is rela-
tively small, the property trajectories in the two groups
(responders versus non-responders) can be very differ-
ent. For the complete responders, tumor is destroyed in
all instances and, based on limited data from dielectric
probe studies, tissue electrical properties trend down-
wards after successful treatment. However, the tissue
characteristics of non-responders are likely to be more
variable because in some cases the tissue properties may
stay the same or be similar whereas in others tumor
progression is likely to yield even higher dielectric prop-
erties over time. As a result, the data point removed
from Patient #2 may not be an actual outlier, but rather
indicative of a more complex tissue behavior that the
non-response might be causing.
Conclusions
We have conducted a preliminary investigation using
MT to monitor the progression of breast cancer
response to neoadjuvant chemotherapy. Early indications
show that the images are repeatable and sensitive to
drug-induced breast changes. Of particular interest is
the response at one month after the start of treatment
where analysis of the conductivity in the ROI was found
to distinguish statistically between the complete and
incomplete (non)-responding patient groups. Early pre-
diction of treatment success (or lack thereof) could pro-
vide useful information to medical oncologists with
respect to altering treatment when a patient is not
responding to the initial therapy. MT could be per-
formed at numerous stages during treatment at rela-
tively low cost and may be particularly attractive for this
type of longitudinal monitoring where the conventional
imaging alternatives (for example, MR; FDG PET) are
less feasible because of cost and inconvenience.
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